For the most part, start-ups begin life with a license to raw technology, at best a couple of compounds in very early development, and little commercial infrastructure. That was not the case with EyeTech Pharmaceuticals Inc. , however, which got its start in large part because it had a development infrastructure, which enabled it to in-license a product from a major biotech company.
Company co-founder David Guyer, MD, a professor of ophthalmology at New York University Medical Center , believed that blocking...






